TGFB1 and neoplasm: CAF-reprogramming strategies aim to transform immunosuppressive CAFs into dormant or tumor-suppressing phenotypes by delivering agents such as TGF-β inhibitors, Hedgehog pathway inhibitors, or epigenetic modulators (48–50).